A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Petrelintide (Primary) ; Petrelintide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Zealand Pharma
- 26 Jun 2023 Results (n=56) assessing safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of ZP8396 in healthy lean and overweight male subjects presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 24 Jun 2023 According to a Zealand Pharma media release, results from this study presented at the 2023 American Diabetes Associations 83rd Scientific Sessions
- 24 Jun 2023 Results published in the Zealand Pharma Media Release